Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

i3 Health

Implementing New Data and Evolving Standards in Metastatic Triple-Negative Breast Cancer

Access Activity

Overview / Abstract:

STATEMENT OF NEED

Breast cancer accounts for approximately 30% of cancer diagnoses among women in the United States and is the second-leading cause of cancer death in this population. About 20% of patients have invasive triple-negative breast cancer (TNBC), which is defined as having estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) negativity. Whereas therapies targeting these receptors have demonstrated efficacy in other breast cancer subtypes, patients with TNBC are instead typically treated with standard chemotherapy, which does not always prove to be effective. While there have been advances with adjuvant chemotherapy, patients with TNBC still have a poorer prognosis than do patients who present with HR-positive or HER2-positive disease; for those with metastatic TNBC, the estimated median overall survival is only 13 months.

TARGET AUDIENCE

Medical oncologists, surgical oncologists, radiation oncologists, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with triple-negative breast cancer (TNBC).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

1. Evaluate clinical and molecular factors that can inform personalized care plans for patients with TNBC
2. Explain guideline recommendations for genetic risk evaluation in patients with TNBC
3. Differentiate emerging efficacy and safety data on novel therapies for metastatic TNBC

Expiration

Mar 31, 2020

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME

Format

Monograph

Credits / Hours

1.0

Accreditation

ACCME, ANCC

Presenters / Authors / Faculty

Sara M. Tolaney, MD, MPH (Chairperson)
Assistant Professor of Medicine
Harvard Medical School

Sara A. Hurvitz, MD
Associate Professor of Medicine
David Geffen School of Medicine at UCLA

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Eisai.

Keywords / Search Terms

i3 Health i3 Health, TNBC, triple-negative breast cancer, breast cancer, oncology, free CE, free CME Free CE CME

Access Activity

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.